Jennifer J. Schlezinger

Jennifer J. Schlezinger

Auto-generated profile, based on publicly available information

Jennifer J. Schlezinger

Department of Environmental Health, Boston University, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TMTiina Matikainen
Tiina Matikainen
GPGloria I. Perez
Gloria I. Perez
AJAndrea Jurisicova
Andrea Jurisicova
JPJames K. Pru
James K. Pru
JSJennifer J. Schlezinger
Jennifer J. Schlezinger
JTJonathan L. Tilly
Jonathan L. Tilly

1 February 2022 in Journal of Hepatology
Verified
Journal Article
Open access
Partho SenPartho Sen
Partho Sen
SQSami Qadri
Sami Qadri
PLPanu K. Luukkonen
Panu K. Luukkonen
OROddny Ragnarsdottir
Oddny Ragnarsdottir
AMAidan McGlinchey
Aidan McGlinchey
Tuulia HyötyläinenTuulia Hyötyläinen
Tuulia Hyötyläinen
Recent experimental models and epidemiological studies suggest that specific environmental contaminants (ECs) contribute to the initiation and pathology of non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanisms linking EC exposure with NAFLD remain poorly understood and there is no data on their impact on the human liver metabolome. Herein, we hypothesized that exposure to ECs, particularly perfluorinated alkyl substances (PFAS), impacts liver metabolism, specifically bile acid metabolism. In a well-characterized human NAFLD cohort of 105 individuals, we investigated the effects of EC exposure on liver metabolism. We characterized the liver (via biopsy) and circulating metabolomes using 4 mass spectrometry-based analytical platforms, and measured PFAS and other ECs in serum. We subsequently compared these results with an exposure study in a PPARa-humanized mouse model. PFAS exposure appears associated with perturbation of key hepatic metabolic pathways previously found altered in NAFLD, particularly those related to bile acid and lipid metabolism. We identified stronger associations between the liver metabolome, chemical exposure and NAFLD-associated clinical variables (liver fat content, HOMA-IR), in females than males. Specifically, we observed PFAS-associated upregulation of bile acids, triacylglycerols and ceramides, and association between chemical exposure and dysregulated glucose metabolism in females. The murine exposure study further corroborated our findings, vis-à-vis a sex-specific association between PFAS exposure and NAFLD-associated lipid changes. Females may be more sensitive to the harmful impacts of PFAS. Lipid-related changes subsequent to PFAS exposure may be secondary to the interplay between PFAS and bile acid metabolism. There is increasing evidence that specific environmental contaminants, such as perfluorinated alkyl substances (PFAS), contribute to the progression of non-alcoholic fatty liver disease (NAFLD). However, it is poorly understood how these chemicals impact human liver metabolism. Here we show that human exposure to PFAS impacts metabolic processes associated with NAFLD, and that the effect is different in females and males.

1 November 2014 in Environmental Health Perspectives
Verified
Journal Article
Open access
HPHari K. Pillai
Hari K. Pillai
MFMingliang Fang
Mingliang Fang
DBDmitri Beglov
Dmitri Beglov
DKDima Kozakov
Dima Kozakov
SVSandor Vajda
Sandor Vajda
JSJennifer J. Schlezinger
Jennifer J. Schlezinger
Background: The use of alternative flame retardants has increased since the phase out of pentabromodiphenyl ethers (pentaBDEs). One alternative, Firemaster® 550 (FM550), induces obesity in rats. Triphenyl phosphate (TPP), a component of FM550, has a structure similar to that of organotins, which are obesogenic in rodents.Objectives: We tested the hypothesis that components of FM550 are biologically active peroxisome proliferator-activated receptor γ (PPARγ) ligands and estimated indoor exposure to TPP.Methods: FM550 and its components were assessed for ligand binding to and activation of human PPARγ. Solvent mapping was used to model TPP in the PPARγ binding site. Adipocyte and osteoblast differentiation were assessed in bone marrow multipotent mesenchymal stromal cell models. We estimated exposure of children to TPP using a screening-level indoor exposure model and house dust concentrations determined previously.Results: FM550 bound human PPARγ, and binding appeared to be driven primarily by TPP. Solvent...

1 September 1999 in Molecular Pharmacology
Verified
Journal Article
Closed access
JSJennifer J. Schlezinger
Jennifer J. Schlezinger
RWRenee D. White
Renee D. White
JSJohn J. Stegeman
John J. Stegeman
Microsomal cytochrome P-450 1A (CYP1A) in a vertebrate model (the teleost fish scup) is inactivated by the aryl hydrocarbon receptor agonist 3,3′,4,4′-tetrachlorobiphenyl (TCB). Here, the mechanism of CYP1A inactivation and its relationship to reactive oxygen species (ROS) formation were examined by using liver microsomes from scup and rat and expressed human CYP1As. In vitro inactivation of scup CYP1A activity 7-ethoxyresorufin O-deethylation by TCB was time dependent, NADPH dependent, oxygen dependent, and irreversible. TCB increased microsomal NADPH oxidation rates, and CYP1A inactivation was lessened by adding cytochrome c. CYP1A inactivation was accompanied by loss of spectral P-450, a variable loss of heme and a variable appearance of P-420. Rates of scup liver microsomal metabolism of TCB were < 0.5 pmol/min/mg, 25-fold less than the rate of P-450 loss. Non-heme iron chelators, antioxidant enzymes, and ROS scavengers had no influence on inactivation. Inactivation was accelerated by H2O2 and azide but not by hydroxylamine or aminotriazole. TCB also inactivated rat liver microsomal CYP1A, apparently CYP1A1. Adding TCB to scup or rat liver microsomes containing induced levels of CYP1A, but not control microsomes, stimulated formation of ROS; formation rates correlated with native CYP1A1 content. TCB stimulated ROS formation by baculovirus-expressed human CYP1A1 but not CYP1A2. The results indicate that TCB uncouples the catalytic cycle of CYP1A, ostensibly CYP1A1, resulting in formation of ROS within the active site. These ROS may inactivate CYP1A or escape from the enzyme. ROS formed by CYP1A1 may contribute to the toxicity of planar halogenated aromatic hydrocarbons.

1 May 2006 in Aquatic Toxicology
Verified
Journal Article
Closed access
JSJennifer J. Schlezinger
Jennifer J. Schlezinger
WSWilliam D.J. Struntz
William D.J. Struntz
JGJed Goldstone
Jed Goldstone
JSJohn J. Stegeman
John J. Stegeman

3 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMargaret M. Lowe
Margaret M. Lowe
JMJeff E. Mold
Jeff E. Mold
BKBittoo Kanwar
Bittoo Kanwar
YHYong Huang
Yong Huang
ALAlexander Louie
Alexander Louie
JMJoseph McCune
Joseph McCune
The aryl hydrocarbon receptor (AHR) binds to environmental toxicants including synthetic halogenated aromatic hydrocarbons and is involved in a diverse array of biological processes. Recently, the AHR was shown to control host immunity by affecting the balance between inflammatory T cells that produce IL-17 (Th17) and IL-22 versus regulatory T cells (Treg) involved in tolerance. While environmental AHR ligands can mediate this effect, endogenous ligands are likely to be more relevant in host immune responses. We investigated downstream metabolites of tryptophan as potential AHR ligands because (1) tryptophan metabolites have been implicated in regulating the balance between Th17 and Treg cells and (2) many of the AHR ligands identified thus far are derivatives of tryptophan. We characterized the ability of tryptophan metabolites to bind and activate the AHR and to increase IL-22 production in human T cells. We report that the tryptophan metabolite, cinnabarinic acid (CA), is an AHR ligand that stimulates the differentiation of human and mouse T cells producing IL-22. We compare the IL-22-stimulating activity of CA to that of other tryptophan metabolites and define stimulation conditions that lead to CA production from immune cells. Our findings link tryptophan metabolism to AHR activation and define a novel endogenous AHR agonist with potentially broad biological functions.